Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India. Issue 6 (6th October 2021)

• Record Type: Journal Article
• Authors: Chauhan, Sanshriti; Meshram, Hari Shankar; Kute, Vivek; Patel, Himanshu; Desai, Sudeep; Dave, Ruchir
• Is Part Of: Transplant infectious disease. Volume 23:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-06
• Subjects: COVID‐19 recovered -- follow‐up -- kidney transplantaion -- post‐COVID‐19 -- quality of life; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.13735
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Introduction: Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported. Methods: We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed. Results: The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%). The most common persistent symptom was fatigue which significantly decreased in the follow‐up ( n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p ‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p ‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up ( n = 4, 3% vs. 7, 5% vs. 3, 2%; p ‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline. Conclusion: Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up.